Can I Take Quercetin with Retatrutide?

What Is Retatrutide and Why Does the Supplement Question Matter?

Retatrutide (LY3437943) is an investigational single-molecule triple agonist targeting the glucose-dependent insulinotropic polypeptide (GIP) receptor, the glucagon-like peptide-1 (GLP-1) receptor, and the glucagon receptor. That three-receptor profile sets it apart from tirzepatide (dual GIP/GLP-1) and semaglutide (GLP-1 only). In the Phase 2 SURMOUNT-like dose-escalation trial published in 2023, participants receiving retatrutide 12 mg subcutaneously once weekly lost a mean of 17.5% of body weight at 24 weeks, compared with 1.6% for placebo, in a 338-participant cohort [1].

Why patients reach for quercetin

People using retatrutide for weight management often stack supplements aimed at anti-inflammatory or metabolic support. Quercetin is among the most popular choices, partly because of its reputation as a natural antihistamine and antioxidant. Annual U.S. Quercetin supplement sales exceeded $200 million as of 2022, and informal patient communities around GLP-1 class drugs frequently discuss it for GI comfort or allergy management.

The core problem with this combination

No published human pharmacokinetic (PK) study has tested quercetin co-administration with retatrutide specifically. That gap means clinicians have to reason from quercetin's known enzyme-inhibition profile and from retatrutide's metabolic pathway. That reasoning process is the focus of this article.

How Retatrutide Is Metabolized

Peptide catabolism, not hepatic CYP

Retatrutide is a fatty-acid-acylated peptide, like semaglutide, and it is cleared primarily through proteolytic degradation and renal filtration rather than hepatic cytochrome P450 metabolism [2]. This is a critical distinction. Because retatrutide itself is not a CYP3A4 substrate in the conventional small-molecule sense, quercetin's CYP3A4 inhibition does not directly raise retatrutide plasma levels the way it might with, say, a statin or a benzodiazepine.

What the peptide pathway means for drug interactions

Peptide-class GLP-1 receptor agonists as a group show a low intrinsic potential for PK drug-drug interactions mediated through CYP enzymes. The FDA label for the structurally related semaglutide (Ozempic/Wegovy) notes that semaglutide caused no clinically meaningful change in the PK of co-administered drugs in dedicated interaction studies [3]. Retatrutide is not yet FDA-approved and lacks a finalized prescribing label, but its acylated-peptide chemistry suggests similar behavior.

Indirect CYP interactions are still possible

Rapid weight loss caused by retatrutide (potentially 20%+ body weight over a treatment course, based on Phase 2 data [1]) can alter drug clearance for other medications a patient takes. Body composition changes affect volume of distribution, renal clearance, and hepatic blood flow. Quercetin itself is absorbed through intestinal epithelium partly via P-glycoprotein (P-gp), and quercetin simultaneously inhibits P-gp and several CYP isoforms, potentially raising systemic exposure to other drugs in the regimen even if retatrutide itself is unaffected.

Quercetin's Enzyme-Inhibition Profile

CYP3A4 and CYP2C9 inhibition: what the evidence says

Quercetin inhibits CYP3A4, CYP2C9, and CYP2C19 in a concentration-dependent manner. A 2004 in-vitro study by Moon et al. Reported IC50 values for quercetin against CYP3A4 in the low-micromolar range, though intestinal concentrations after a 500 mg oral dose may reach levels sufficient to produce meaningful inhibition in the gut wall [4]. A human crossover study by Choi et al. (N=12) showed that 1,500 mg/day quercetin for 7 days increased the AUC of the CYP3A4 substrate felodipine by approximately 36% [5]. That is a clinically moderate interaction.

P-glycoprotein inhibition

P-gp sits at the blood-gut barrier and acts as an efflux pump for many drugs. Quercetin inhibits P-gp at concentrations achievable in intestinal tissue after supplemental doses [6]. For retatrutide, which is absorbed subcutaneously and bypasses first-pass intestinal processing entirely, this particular mechanism matters less for the drug itself. It matters more for other medications in a patient's regimen that depend on P-gp efflux.

What doses of quercetin actually inhibit enzymes?

Standard supplement doses range from 250 mg to 1,000 mg daily. The Choi et al. Interaction study used 1,500 mg/day, higher than most commercial products. At 500 mg/day, intestinal CYP3A4 inhibition is less pronounced but not zero. The dose-dependency means a patient taking 250 mg quercetin daily has a different risk profile than one taking a "quercetin phytosome" product at 800 mg combined with bromelain.

The Antihistamine and Mast-Cell Overlap

Quercetin as a mast-cell stabilizer

Quercetin inhibits IgE-dependent histamine release from mast cells and basophils. A 2016 in-vitro study by Finn et al. Reported that quercetin at 10 to 100 micromolar concentrations suppressed calcium-ionophore-stimulated histamine release by 40 to 80% [7]. Many patients add quercetin to their regimen specifically for this effect, describing reduced allergy symptoms.

GLP-1 receptors and mast cells

GLP-1 receptors are expressed on mast cells, and GLP-1 receptor agonists have been shown to modulate mast-cell degranulation in preclinical models. A 2022 rodent study published in the Journal of Allergy and Clinical Immunology found that liraglutide reduced IgE-mediated mast-cell degranulation by approximately 30% in sensitized mice [8]. Retatrutide adds GIP and glucagon receptor agonism on top of that GLP-1 effect. Whether this translates to a clinically meaningful additive antihistamine effect in humans taking quercetin alongside retatrutide is unknown.

Practical implication of the overlap

Combining two mast-cell-stabilizing agents is unlikely to be dangerous in a healthy person. The theoretical concern is amplified hypotension in susceptible individuals (mast-cell suppression can lower baseline histamine tone, and both vasodilatory and gastrointestinal histamine pathways may be affected). There is no reported case of clinically significant hypotension from this specific combination, but monitoring blood pressure for the first 2 to 4 weeks of concurrent use is reasonable.

Gastrointestinal Side-Effect Amplification

Retatrutide's most common adverse effects are nausea, vomiting, diarrhea, and constipation, reported in 30 to 60% of participants at escalating doses in Phase 2 [1]. Quercetin in high doses (above 1,000 mg/day) can cause headache and GI discomfort in some patients. There is no specific evidence that quercetin worsens GLP-1-class GI side effects, but adding any supplement that independently causes GI symptoms during dose escalation of a GLP-1/GIP/glucagon agonist complicates clinical interpretation. If nausea worsens, your provider cannot easily tell whether it is retatrutide escalation, quercetin, or both.

Timing of quercetin during dose escalation

Retatrutide Phase 3 protocols typically escalate the dose stepwise over 12 to 24 weeks before reaching a maintenance dose. GI side effects are most intense during escalation. Starting quercetin for the first time during this window adds a confounding variable. A more conservative approach: stabilize on retatrutide's maintenance dose before introducing quercetin, then introduce quercetin at the lowest available dose (250 mg/day) and titrate upward only if tolerated.

Pharmacodynamic Interactions Beyond Histamine

Blood glucose effects

Quercetin has modest glucose-lowering properties in animal models, primarily through GLUT4 translocation and alpha-glucosidase inhibition. A 2011 meta-analysis by Mahmoud et al. Found no statistically significant fasting glucose reduction in human trials [9]. Retatrutide's glucose-lowering effect is far larger and mechanistically distinct. The risk of clinically meaningful additive hypoglycemia from quercetin added to retatrutide alone (without insulin or sulfonylurea) is considered low.

Lipid and inflammatory effects

Both agents have anti-inflammatory properties in preclinical models. Quercetin reduces TNF-alpha and IL-6 in cell culture studies. Retatrutide's Phase 2 participants showed reductions in high-sensitivity CRP and other inflammatory markers alongside weight loss [1]. An additive anti-inflammatory effect from combining both is plausible but has not been measured in humans and is not a safety concern at typical supplement doses.

Dose-Separation Strategy

The following framework is designed by the HealthRX medical team to help clinicians and patients structure quercetin use around retatrutide injections. It is based on quercetin's oral absorption kinetics (Tmax approximately 0.5 to 1 hour; half-life approximately 3.5 hours for the parent compound) and retatrutide's subcutaneous route, which bypasses any intestinal interaction entirely.

Step 1. Confirm which medications in your full regimen are CYP3A4 or P-gp substrates. Quercetin's interaction risk with retatrutide itself is low. The risk to other drugs (statins, thyroid hormone, calcium channel blockers, anticoagulants) in your stack is higher and must be reviewed first.

Step 2. Begin quercetin only after reaching retatrutide's stable maintenance dose. Do not introduce quercetin during the dose-escalation phase.

Step 3. Start at 250 mg quercetin once daily with a meal. Most interaction studies showing CYP inhibition used doses of 1,000 mg or higher. A 250 mg starting dose minimizes enzyme-inhibition risk while still providing the intended antioxidant and mast-cell effects.

Step 4. If you take other oral medications that are CYP3A4 substrates, separate quercetin from those medications by at least 2 hours. Because retatrutide is given subcutaneously, there is no injection-site timing consideration with quercetin.

Step 5. Monitor for GI symptoms, blood pressure, and any unexpected changes in the efficacy or side effects of other medications during the first 4 weeks. Report changes to your prescriber promptly.

What Current Guidelines and Databases Say

The Natural Medicines Comprehensive Database assigns quercetin a "moderate" interaction rating with drugs that are CYP3A4 substrates, noting that quercetin "may increase or decrease" drug levels depending on the specific substrate and dose [10]. Because retatrutide is not itself a classical CYP3A4 substrate (it is a peptide), this broad rating applies more to other drugs in the patient's regimen than to retatrutide directly.

The Endocrine Society's 2023 clinical practice guideline on obesity pharmacotherapy does not specifically address quercetin co-administration with any GLP-1 class drug [11]. The guideline does state: "Patients initiating pharmacotherapy for obesity should have all dietary supplements reviewed by their clinician to identify potential interactions with co-prescribed medications." That instruction applies directly here.

No FDA drug interaction guidance exists for retatrutide because the drug remains investigational. Eli Lilly's Phase 3 protocols for LY3437943 list no specific supplement exclusion criteria in publicly available summaries on ClinicalTrials.gov [12].

Special Populations

Patients on polypharmacy

A patient taking retatrutide plus warfarin or a narrow-therapeutic-index drug (e.g., cyclosporine or tacrolimus) faces the highest real-world risk from quercetin addition. Cyclosporine's oral bioavailability depends on intestinal CYP3A4 and P-gp. Quercetin 500 mg/day may raise cyclosporine AUC by 20 to 40% based on P-gp inhibition data, a range sufficient to cause toxicity [6]. For these patients, quercetin is best avoided until their transplant or immunology team reviews the full regimen.

Patients with mast cell activation syndrome (MCAS)

Some clinicians prescribe quercetin therapeutically at 500 to 1,000 mg twice daily for MCAS. In this population, the additive mast-cell-stabilizing effect of a GLP-1 class drug could theoretically be beneficial. No clinical data support this, but the combination is used off-label and anecdotally reported in MCAS patient communities. Blood pressure and GI tolerance should be monitored.

Pregnancy and lactation

Retatrutide carries no FDA pregnancy category label because it is investigational. Quercetin crosses the placenta in animal models [13]. Neither agent has established safety in human pregnancy. Patients who are pregnant or breastfeeding should not take either compound outside a supervised clinical trial.

Monitoring Checklist for Clinicians

If a patient on retatrutide wishes to add quercetin, the following monitoring approach is appropriate at the initial conversation and at the 4-week follow-up visit.

• Full medication reconciliation including dose and brand of quercetin product (some contain bromelain or other bioenhancers that further affect absorption).
• CYP3A4 substrate review of all other oral medications; adjust monitoring frequency for narrow-TI drugs.
• Baseline blood pressure if the patient has any history of orthostatic hypotension or mast-cell disorder.
• GI symptom diary for the first 4 weeks of concurrent use, particularly during ongoing retatrutide dose titration.
• Lipid panel and fasting glucose at standard retatrutide follow-up intervals; quercetin's modest glycemic effects do not require additional labs.